1. Healthcare

  2. •

    Medical - Equipment & Services
Mazor Robotics Ltd.

Mazor Robotics Ltd.

MZOR
Mazor Robotics Ltd.US flagNASDAQ
58.23
USD
- -
- -
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
0.08
0.18
0.42
0.51
1.01
1.12
1.01
1.23
1.62
2.64
2.27
Basic EPS, GAAP
-0.74
-0.59
-0.62
-0.67
-0.59
-1.15
-0.73
-0.73
-0.83
-0.51
-0.84
Free Cash Flow per Basic Share
-0.73
-0.49
-0.49
-0.61
-0.18
-0.3
-0.71
-0.58
-0.56
-0.34
-0.18
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-4.46
-4.31
-4.3
-4.33
-4.05
-4.2
-4.88
-5.42
-5.46
-5.96
Tangible Book Value per Share
- -
2.4
1.43
1.18
1.04
3.58
2.6
2.01
2.79
4.55
4.2
Basic Weighted Avg Shares
7
8
10
11
12
18
21
21
22
25
26
Sales/Revenue/Turnover
1
1
4
6
12
20
21
26
36
65
59
Operating Margin (%)
-994.27
-305.66
-133
-128
-34.58
-34.67
-69.35
-58.66
-52.29
-21.25
-39
Depreciation Expense
- -
- -
- -
- -
1
1
1
1
1
2
2
Net Income, GAAP
-5
-5
-6
-7
-7
-21
-15
-15
-19
-12
-22
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.83
Profit Margin (%)
-938.3
-320.53
-144.98
-129.96
-58.02
-102.73
-72.01
-58.96
-51.32
-19.12
-36.9
Working Capital
- -
22
18
13
16
63
48
36
50
102
104
LT Debt
- -
3
3
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
19
15
14
13
64
54
42
65
114
112
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.71
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
53
53
53
Market Capitalization
1,543
1,427
1,528

Working Capital

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
121
124
127
Cash, Cash Equivalents & STI
109
104
107
Accounts Receivable, Net
2
9
9
Inventories
8
7
7
Total Current Liabilities
15
17
23
Payables & Accruals
3
3
4
ST Debt
- -
- -
- -
Deferred Revenue
3
6
8

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
98.22%
75.32%
Free Cash Flow
- -
54.3%
-33.76%
Net Income, GAAP
- -
30.72%
-33.47%
Sales/Revenue/Turnover
- -
42.25%
78.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
6
8
8
14
36
2017
12
15
17
21
65
2018
16
13
10
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.24
-0.19
-0.23
-0.18
-0.83
2017
-0.22
-0.15
-0.15
0.01
-0.51
2018
-0.05
-0.15
-0.64
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
Sector
Healthcare
Industry
Medical - Equipment & Services
Address
IPO Date
May 28, 2013
CIK
0001566844
Similar Companies
Pharmerica Corporation (PMC)
Concentra Group Holdings Parent, Inc. (CON)
Hologic, Inc. (0J5Q.L)
Sirona Dental Systems, Inc. (SIRO)
Prime People Plc (PRP.L)
Hi-Clearance Inc. (1788.TWO)
Business
Mazor Robotics Ltd, an Israel-based medical device company founded in 2001 and headquartered in Caesarea, develops and markets robotic guidance systems for spine and brain surgery; its core products include the Renaissance Guidance System for precise implant placement in procedures such as percutaneous degenerative repair, pedicle screw fixation, and vertebral augmentation, and the Mazor X Surgical Assurance Platform, which provides preoperative planning, intraoperative navigation, real-time 3D verification, and connectivity features for minimally invasive spinal surgeries. Medtronic plc completed its acquisition of Mazor Robotics in December 2018 for approximately $1.7 billion, integrating the technology into its Restorative Therapies Group to combine with spine implants, StealthStation navigation, 3D imaging, and powered surgical tools like the Midas Rex high-speed drills. Recent enhancements under Medtronic include the Mazor X Stealth Edition cleared by the FDA in early 2019 for seamless software integration, software version 5.1 launched in 2024 with AI capabilities, bone cutting, and graft delivery as part of the AiBLE spine surgery ecosystem, and ongoing FDA registrations active as of 2025, expanding applications to patient-specific rods, osteotomies, and interbody cages while serving surgeons and hospitals globally across four continents.

Company News

APIChat

  • globenewswire.com

    MeMed Bolsters Leadership Team With Appointment of Ori Hadomi as Chairman and Peter Scheu as President of MeMed US